Endomyocardial Biopsy Market
Report ID: SQMIG35A3732
Report ID: SQMIG35A3732
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3732 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
152
|Figures:
78
Global Endomyocardial Biopsy Market size was valued at USD 432.5 Million in 2024 and is poised to grow from USD 460.61 Million in 2025 to USD 762.31 Million by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).
Driven primarily by rising transplant volumes and growing incidence of myocarditis, the endomyocardial biopsy industry centers on instruments, bioptomes, imaging guidance, laboratory analysis and services used to obtain and evaluate myocardial tissue for diagnosis and management. The market matters because EMB remains the diagnostic gold standard for cardiac transplant rejection and inflammatory cardiomyopathies, where histology guides immunosuppression and therapy decisions. Historically the field evolved from blind, fluoroscopy dependent sampling to image guided procedures and integration with molecular diagnostics, increasing safety and diagnostic yield.
For example, routine EMB protocols in transplant centers and transcriptomic rejection assays illustrate expanding market scope.Building on that clinical and technological foundation, the primary growth engine for the global endomyocardial biopsy market is innovation that reduces procedural risk while increasing diagnostic granularity, which in turn expands clinician confidence and adoption. As manufacturers introduce smaller bioptomes, real time intracardiac imaging and assays profile gene expression, centers can detect subclinical rejection or drug induced myocarditis earlier, prompting quicker therapeutic interventions and better outcomes. This cause and effect dynamic opens opportunities across device sales, laboratory services and software analytics, driving investment in training, reimbursement negotiations, especially emerging markets where rising transplant volumes and cardio oncology cases elevate demand.
How is AI improving diagnostic accuracy in the endomyocardial biopsy market?
AI is improving diagnostic accuracy in the endomyocardial biopsy market by combining image analysis, pattern recognition, and molecular profiling to reduce human variability and highlight subtle tissue changes. Key aspects include automated histology review, machine learning guided sampling, and integration of gene expression with imaging to sharpen diagnostic context. The current state shows research grade and emerging clinical tools that assist pathologists and transplant teams, making biopsy interpretation more consistent and informative. Examples include deep learning models that flag rejection patterns and predictive scores that guide whether a biopsy will yield diagnostic tissue, improving clinical confidence and workflow.
CareDx in March 2026, the company launched VANTx, an AI powered clinical data and analytics platform, which links molecular tests and biopsy information to generate predictive insights. This innovation supports market efficiency by standardizing interpretation of endomyocardial biopsy data and enabling faster, more reliable clinical decisions.
Market snapshot - (2026-2033)
Global Market Size
USD 432.5 Million
Largest Segment
Biopsy Forceps
Fastest Growth
Imaging & Guidance Systems
Growth Rate
6.5% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global endomyocardial biopsy market is segmented by product type, procedure type, guidance modality, indication, end user and region. Based on product type, the market is segmented into Biopsy Forceps, Bioptomes, Catheters & Introducer Sheaths, Imaging & Guidance Systems, Sample Collection and Preservation Kits and Others. Based on procedure type, the market is segmented into Right Ventricular Endomyocardial Biopsy, Left Ventricular Endomyocardial Biopsy and Biventricular Endomyocardial Biopsy. Based on guidance modality, the market is segmented into Fluoroscopy-Guided Biopsy, Echocardiography-Guided Biopsy, MRI-Guided Biopsy and Others. Based on indication, the market is segmented into Heart Transplant Rejection Monitoring, Myocarditis Diagnosis, Cardiomyopathy Evaluation, Cardiac Amyloidosis Assessment, Infiltrative & Inflammatory Heart Disease Diagnosis and Others. Based on end user, the market is segmented into Hospitals, Cardiac Specialty Centers, Transplant Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Biopsy forceps segment dominates with large endomyocardial biopsy market share because established procedural familiarity and broad compatibility with existing catheter platforms make forceps the default tissue retrieval option in endomyocardial biopsy procedures. Their mechanical reliability produces consistent core samples, lowering the need for repeat sampling and streamlining workflow, which reinforces clinician preference. Continuous incremental design improvements, strong supplier networks, and entrenched training pathways sustain procurement and routine use across care settings, maintaining market leadership.
As per endomyocardial biopsy market outlook, imaging & guidance systems are the fastest growingsegment as advanced visualization tools expand operator confidence and procedural success. Integrated imaging, fusion mapping, and real-time navigation improve target localization and reduce complications, prompting adoption by centers focused on precision diagnostics and enabling new high-value equipment procurement and service opportunities.
As per endomyocardial biopsy market forecast, echocardiography guided biopsy segment leads because ready availability of echocardiographic imaging and its real-time soft tissue visualization enable safer, image-informed sampling during endomyocardial biopsy procedures. Bedside accessibility and integration with catheterization workflows reduce procedural complexity and reliance on ionizing radiation, encouraging clinician acceptance. Ongoing improvements in transesophageal and intracardiac echo technology, paired with targeted operator training, enhance diagnostic yield and institutional adoption across cardiology services.
As per endomyocardial biopsy market analysis, MRI guided biopsy is witnessing the strongest growth as demand for precise tissue targeting and superior soft tissue contrast rises in complex diagnostics. Improvements in MRI compatible tools, procedural workflows, and growing clinical evidence support broader adoption. This momentum drives development of specialized devices and expands high-value diagnostic options.
To get detailed segments analysis, Request a Free Sample Report
As per endomyocardial biopsy market regional outlook, North America is expected to dominate the regional outlook for the endomyocardial biopsy market, owing to a combination of strong healthcare infrastructure, concentrated industry leadership, and clinical competence. Major medical centers and specialized cardiology programs routinely employ sophisticated biopsy techniques that permit rapid implementation of operational changes. A supportive regulatory and reimbursement environment allows for market access of novel platforms and consumables, while well-established referral pathways and diagnostic laboratories provide for stable procedure volumes. Guideline development and practitioner training are driven by a strong presence of device makers, active clinical research networks, and professional societies. Strong service support and distribution channels help in the procurement of hospitals and clinics. Collaborative ties between clinicians, industry and payers further fuel the drive for demand and innovation, and cement North America as the market leader in endomyocardial biopsy technology and clinical practice.
As per endomyocardial biopsy market regional forecast, United States is driven by tertiary hospitals and transplant centers that commonly include biopsy in diagnostic and surveillance pathways. Adoption of procedural modifications is supported by clinician skill, closeness to developers, and vigorous academic activity. The development of multidisciplinary teams and specialised pathology services has improved the interpretation of specimens. Well-established procurement and service channels across large metropolitan hospital networks guarantee reliable access to instruments and disposables.
As per endomyocardial biopsy industry analysis, Canada relies on provincial cardiac programs and academic hospitals for centralizing expertise in procedures and pathology interpretation. Publicly funded health care systems impact access patterns and procurement tactics, often privileging centralized centers of excellence and interprovincial referrals. Clinical adoption is supported by collaboration between clinicians and device suppliers and training activities. Telepathology and centralized laboratory networks provide diagnostic reach to less populated areas and coordinated referral pathways maintain high procedural quality.
In Europe, the endomyocardial biopsy market is rising fast fuelled by growing clinical acceptance of the use of biopsy for transplant surveillance and complex cardiomyopathies, and helped along by improvements to the region's healthcare infrastructure. In numerous countries, key legislative procedures and reimbursement reforms have enhanced access to established technology. Active academic networks and multicenter collaborations enable common protocols and training. Device makers and service providers concentrated in continental hubs assist supply and clinician support. Cross-border referrals and core pathology services and centre of excellence models provide for an efficient concentration of cases and quality control. Greater involvement between industry, professional associations and payers drives guideline alignment and increased adoption of standardized biopsy techniques across different healthcare systems, strengthening Europe as a fast-growing regional market.
Germany is anchored by a dense network of hospitals and specialized cardiology centers that drive clinical adoption. Strong domestic device and diagnostics industries support localized innovation and supply, while coordinated clinical research and guideline contribution enhance procedural standardization. Developed hospital infrastructure and training programs ensure procedural competence, and established reimbursement mechanisms facilitate integration of biopsy into routine care pathways across major regional centers and referral hospitals.
United Kingdom is gaining momentum through integrated care initiatives and strong translational research linking academic hospitals and industry partners. Expansion of specialist cardiac networks and targeted training programs enhances clinician proficiency and spreads technique. Regulatory clarity and projects support adoption of advanced biopsy tools, while centralized pathology and referral structures concentrate complex cases. Engagement among professional societies and healthcare commissioners advances guideline acceptance and clinical integration.
France is emerging through development of specialized cardiac units and strengthened collaboration between teaching hospitals. Investment in clinical research and evidence generation increases clinician confidence in biopsy procedures. Health authority engagement and evolving reimbursement approaches encourage adoption in centers of expertise. Partnerships with device suppliers, consolidated pathology services, and focused training initiatives support capacity building, while referral networks help concentrate complex cases and ensure procedural quality.
Asia Pacific is improving its position in the endomyocardial biopsy market by focused investment in improved cardiac care, enhanced clinical competence, and strategic partnerships with global equipment makers. Existing centres in regional hubs are improving procedural skills and pathology support, and regulatory processes are maturing in various markets to accept innovative technology. Partnering with local production and distribution strengthens supply resilience and expands market reach. Training efforts, visiting proctor programs and university collaborations speed up the transfer of skills. Centralised laboratories and telepathology increase diagnostic capabilities beyond the big cities. A combination of public and corporate sector activities, increased clinical trial participation and greater awareness across cardiology networks are making the Asia Pacific area an increasingly influential location in biopsy uptake and clinical practice. Increased investment in diagnostic infrastructure and stronger networks for patient referral mean greater clinical deployment and adherence to rising standards of quality.
Japan has state-of-the-art cardiology centers and a robust medical device ecosystem that fosters clinical innovation. This close partnership between academia and industry enables evaluation of the devices, training of clinicians, and modification of the protocols. Pathology services and hospital networks provide reliable analysis of specimens. Established referral procedures concentrate complex cases in specialist institutions. Regulatory interaction and emphasis on evidence development boost uptake of biopsy methods throughout therapeutic contexts.
South Korea boasts a modern hospital system and is proactive in its adoption of innovative procedural techniques. Close relationships between manufacturers and partners accelerate instrument availability, and centers of excellence in cardiology support clinician training and standardization of protocols. Digital platforms and centralized pathology services provide rapid evaluation of specimens. Government health programs and university collaborations are promoting clinical research with a view to integrating biopsy into specialty care pathways at scale.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Need For Diagnostic Precision
Technological Advancements In Devices
Procedure Associated Safety Concerns
Limited Reimbursement and Coverage
Request Free Customization of this report to help us to meet your business objectives.
Competitive activity in the global endomyocardial biopsy industry centers on imaging and device innovation, targeted partnerships, and selective acquisitions. Established medtech firms pursue acquisitions to add catheter platforms while vendors partner with clinical centers to validate image guided approaches, exemplified by Abiomed acquisitions and Mayo Clinic collaborations, and by MRI guided and micro biopsy developments from Imricor and Microcardix.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global endomyocardial biopsy market growth is propelled by rising transplant volumes as a key driver and by rapid advances in imaging and molecular diagnostics as a second driver, which together improve diagnostic precision and broaden procedural indications. Adoption remains constrained by procedure associated safety concerns that limit uptake in lower-volume centers. North America remains the dominating region owing to concentrated transplant programs, strong reimbursement and industry presence, while biopsy forceps continue as the dominating segment because of clinician familiarity, consistent specimen quality and wide platform compatibility. Continued device innovation, training and integrated diagnostics will shape market growth and clinical acceptance.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 432.5 Million |
| Market size value in 2033 | USD 762.31 Million |
| Growth Rate | 6.5% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Endomyocardial Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Endomyocardial Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Endomyocardial Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Endomyocardial Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Endomyocardial Biopsy Market size was valued at USD 432.5 Million in 2024 and is poised to grow from USD 460.61 Million in 2025 to USD 762.31 Million by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).
Competitive activity in the global endomyocardial biopsy market centers on imaging and device innovation, targeted partnerships, and selective acquisitions. Established medtech firms pursue acquisitions to add catheter platforms while vendors partner with clinical centers to validate image guided approaches, exemplified by Abiomed acquisitions and Mayo Clinic collaborations, and by MRI guided and micro biopsy developments from Imricor and Microcardix. 'Argon Medical Devices, Inc.', 'Cordis', 'Mermaid Medical A/S', 'Terumo Corporation', 'Scholten Surgical Instruments, Inc.', 'Changzhou Lookmed Medical Instrument Co., Ltd.', 'Fehling Instruments GmbH & Co. KG', 'Medtronic plc', 'Boston Scientific Corporation', 'Teleflex Incorporated', 'Cook Medical LLC', 'Merit Medical Systems, Inc.', 'Olympus Corporation', 'Integer Holdings Corporation', 'B. Braun SE', 'Biotronik SE & Co. KG', 'Edwards Lifesciences Corporation', 'Abbott Laboratories', 'Lepu Medical Technology Co., Ltd.', 'Oscor Inc.'
Endomyocardial biopsy is increasingly sought to provide definitive tissue diagnosis for complex cardiac conditions, which strengthens demand for biopsy devices and services. Clinicians rely on histopathological confirmation to guide targeted therapies and management, and the procedure supports differentiation among overlapping cardiomyopathies and inflammatory disorders. As diagnostic certainty becomes more valued within care pathways, healthcare providers prioritize access to biopsy capabilities, thereby encouraging investment in training, infrastructure, and device adoption across centers that manage advanced cardiac disease.
𝗠𝗶𝗻𝗶𝗺𝗮𝗹𝗹𝘆 𝗜𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗔𝗱𝗼𝗽𝘁𝗶𝗼𝗻: The clinical preference is shifting toward less invasive tissue sampling and improved patient experience, driving demand for refined biopsy catheters, enhanced imaging guidance and integrated procedural platforms. Manufacturers emphasize ergonomic designs and operator training to expand use in ambulatory settings and cardiology clinics. Cross-disciplinary collaboration with imaging specialists and device developers promotes workflow efficiency and reduced procedure times, supporting broader acceptance among clinicians and healthcare providers focused on safer, patient-centered diagnostic pathways and streamlined peri-procedural care and optimized device availability.
Why does North America Dominate the Global Endomyocardial Biopsy Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
